Your browser doesn't support javascript.
loading
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz, Ewa; Jacob, Lisa; Greenwald, Shirley; Tamir, Ami; Pecker, Iris; Tabakman, Rinat; Ghantous, Lucy; Tamir, Liat; Kahn, Roy; Avichzer, Jasmine; Aronin, Alexandra; Amsili, Shira; Zorde-Khvalevsky, Elina; Gozlan, Yosi; Vlaming, Martijn; Huls, Gerwin; van Meerten, Tom; Dranitzki, Michal Elhalel; Foley-Comer, Adam; Pereg, Yaron; Peled, Amnon; Chajut, Ayelet; Bremer, Edwin.
Afiliação
  • Cendrowicz E; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
  • Jacob L; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
  • Greenwald S; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Tamir A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Pecker I; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Tabakman R; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Ghantous L; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Tamir L; Departments of Nephrology and Hypertension, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
  • Kahn R; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Avichzer J; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Aronin A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Amsili S; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Zorde-Khvalevsky E; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Gozlan Y; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel.
  • Vlaming M; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Huls G; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
  • van Meerten T; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
  • Dranitzki ME; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
  • Foley-Comer A; Departments of Nephrology and Hypertension, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
  • Pereg Y; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Peled A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel.
  • Chajut A; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel.
  • Bremer E; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. ayelet@kahrbio.com.
J Exp Clin Cancer Res ; 41(1): 97, 2022 Mar 14.
Article em En | MEDLINE | ID: mdl-35287686
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Antígeno CD47 / Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral / Imunidade Inata Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Antígeno CD47 / Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral / Imunidade Inata Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda